CMMB — Chemomab Therapeutics Ltd DRC
NASDAQ · Healthcare · Biotechnology
$2.83
+$0.10 (+3.48%)
Chemomab Therapeutics Ltd DRC (CMMB) is a biotechnology company listed on NASDAQ. It is led by Adi Mor George Ph.D., based in Building 7, Tel Aviv, Israel, 6158002. Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Net income was -$8.8M. CMMB currently screens at market cap $22.2M.
Use this CMMB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CMMB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CMMB SEC filings page. Lician reads the product cache first so this HTML stays unique to Chemomab Therapeutics Ltd DRC even when a live quote feed is slow.
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
CMMB Key Statistics
Market Cap
$22.16M
Volume
139,562
Previous Close
$2.17
Day Range
$2.12 – $2.37
EPS
$0.12
Revenue
$0.00
Net Income
-$27.65M
Gross Profit
$0.00
Free Cash Flow
$0.00
CMMB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$27.65M | -$12.48M | -$5.95M | -$27.12M |
| EPS (Diluted) | $0.12 | $0.06 | $0.00 | $0.00 |
Total Assets
$43.06M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$13.52M
Operating Cash Flow
-$20.37M
Free Cash Flow
$0.00
Chemomab Therapeutics Ltd DRC Company Information
- Co-Founder, Chief Scientific Officer, CEO & Executive Director
- Adi Mor George Ph.D.
- Headquarters
- Building 7, Tel Aviv, Israel, 6158002
- Website
- www.chemomab.com
- Phone
- 972 77 331 0156
- IPO / Founded
- 2019-02-12
- Sector
- Healthcare
- Industry
- Biotechnology